Vera Therapeutics stock rocketed nearly 70% on Monday on upbeat data for a kidney-disease trial. Shares are tumbling Friday ...

Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

MAIA’s Chairman and CEO Vlad Vitoc, M.D., expressed optimism regarding the results, stating, "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC ...